Fluvastatin Converts Human Macrophages into Foam Cells with Increased Inflammatory Response to Inactivated .

Cholesterol biosynthesis inhibitors (statins) protect hypercholesterolemic patients against developing active tuberculosis, suggesting that these drugs could help the host to control the pathogen at the initial stages of the disease. This work studies the effect of fluvastatin on the early response of healthy peripheral blood mononuclear cells (PBMCs) to inactivated . We found that in fluvastatin-treated PBMCs, most monocytes/macrophages became foamy cells that overproduced NLRP3 inflammasome components in the absence of immune stimulation, evidencing important cholesterol metabolism/immunity connections.

Optimisation of the quality of care for patients with severe asthma: ASfarMA project.

 Severe asthma has an important impact on patients and healthcare resources. Recently, the new specific treatments have defined a new scenario in which person-focused care and specialist multidisciplinary teams are necessary. Our Severe Asthma Unit (SAU) started the ASfarMA project along with an external human-centered design company to understand patients' vision of their illness, treatment, and healthcare experience, and to define the ideal SAU by performing a core group session, in-depth semistructured interviews and co-creation workshop.

Genetic and flow cytometry analysis of seronegative celiac disease: a cohort study.

Seronegative celiac disease (CD) poses a diagnostic challenge. Characterize and identify differences between seronegative and seropositive CD. Retrospective cohort study examining adult patients diagnosed with CD (1980-2017).